




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A23K 1/00, 1/18, 1/16, A61K 31/205	A1	(11) International Publication Number: WO 00/00039 (43) International Publication Date: 6 January 2000 (06.01.00)
(21) International Application Number: PCT/US99/14009 (22) International Filing Date: 22 June 1999 (22.06.99) (30) Priority Data: 60/090,882 26 June 1998 (26.06.98) US (71) Applicant: THE IAMS COMPANY [US/US]; 7250 Poe Avenue, Dayton, OH 45414-5801 (US). (72) Inventors: SUNVOLD, Gregory, Dean; 651 Snedsted, Eaton, OH 45320 (US). TETRICK, Mark, Alan; 7242 Robert Ulrich Avenue, Dayton, OH 45415 (US). DAVENPORT, Gary, Mitchell; 4020 Shell Avenue, Dayton, OH 45415 (US). (74) Agents: HAGAN, Timothy, W. et al.; Killworth, Gottman, Hagan & Schaeff, L.L.P., One Dayton Centre - Suite 500, One South Main Street, Dayton, OH 45402-2023 (US).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: PROCESS AND PRODUCT FOR PROMOTING WEIGHT LOSS IN OVERWEIGHT DOGS

**(57) Abstract**

A process for feeding a pet food supplement or diet to an overweight canine for the purpose of promoting weight loss, and/or increasing lean body mass, and/or enhancing the satiety of the animal is provided. The supplement or diet contains an effective amount of L-carnitine.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

-1-

PROCESS AND PRODUCT FOR PROMOTING WEIGHT LOSS IN OVERWEIGHT DOGS

The present invention relates to a process and product for promoting weight loss in overweight dogs, and more particularly to a process for supplementing a
5 canine diet with L-carnitine to promote weight loss, improve body composition, and enhance satiety in the animal.

It is estimated that 20 to 40% of the canine population is overweight or obese. This represents a very large number of animals that are in need of a means to lose weight. Obesity and being overweight are conditions associated with several health
10 risks such as diabetes, increased blood pressure, increased blood triglycerides, impaired locomotion, skeletal stress, increased dystocia, thyroid dysfunction, etc. Consequently, ways to help treat these conditions are much needed by this population of animals. Currently, the most common form of treating obesity in dogs is through the use of diets that contain high amounts of fiber to dilute the calories of the
15 diet.

While in some cases these diets can be effective, they are often associated with several side effects. These include: 1) excessive stool output, 2) decreased nutrient digestibility, 3) poor skin and haircoat, 4) decreased palatability, and 5) constipation and(or) increased frequency of defecation. As a result, alternative
20 nutritional means to alleviate these conditions are needed.

Recently, it has been reported that carnitine, a vitamin-like substance, increased oxidation of octanoate in newborn pigs (van Kempen and Odle, *J. Nutr.* 125:238-250 (1995)), lowered fat deposition and increased fatty acid oxidation by hepatic cells in growing salmon (Ji et al, *J. Nutr.* 126:1937-1950 (19996)), and
25 decreased body fat accumulation in growing pigs (Owen et al, *J. Anim. Sci.* 74:1612-1619 (1996)).

Accordingly, there is still a need for addressing the obesity problems of canines while still providing adequate nutrition and without the side effects associated with prior diets.

-2-

The present invention addresses the problem of obese and overweight canines through the use of a diet which contains supplemental L-carnitine. L-carnitine is an amino acid co-factor which is synthesized in an animal's body from the amino acids lysine and methionine. We have discovered that L-carnitine, when
5 administered to a canine in need of treatment at extremely low supplemental amounts of 100 mg/kg of diet or less, promotes weight loss in the animal, improves the animal's body composition, and results in enhanced satiety in the animal. By improving the animal's body composition we mean that for a given animal ingesting a given amount of food, the percentage of body fat in the animal will be lower and the
10 percentage of lean body mass will be higher when the animal is provided with the effective amount of supplemental L-carnitine as compared with an animal ingesting the same amount of food, but without L-carnitine supplementation. The L-carnitine may be provided to the animal either as a supplement or contained in a diet fed to the animal. Such a supplement may be in the form of a pill or capsule, a treat or biscuit,
15 or any other edible form. By "diet" we mean the food or drink regularly consumed by the animal.

In accordance with one aspect of the invention, a process for promoting weight loss in canines is provided and includes the step of administering to a canine an effective amount of L-carnitine for a time sufficient to effect a reduction in the weight
20 of the animal. In one embodiment, the L-carnitine may be administered in a diet containing supplemental L-carnitine in an amount of from about 15 to about 195 mg/kg, and preferably from about 25 to about 150 mg/kg of diet. The diet preferably comprises from about 18 to 40 wt% crude protein, about 4 to 30 wt% fat, and about 2 to 20 wt% total dietary fiber, and the L-carnitine is present in the diet in a
25 concentration of between about 15 to about 195 ppm, more preferably about 25 to about 150 ppm, and most preferably about 50 to about 100 ppm.

In another embodiment of the invention, the L-carnitine is administered as a supplement in an amount of from between about 1 to about 100 mg L-carnitine per day, and more preferably from between about 2.5 to about 50 mg L-carnitine per day.
30 Practice of the present invention is also useful in increasing the lean body

mass of a canine as well as enhancing the satiety and decreasing voluntary food intake of a canine.

Accordingly, it is a feature of the invention to provide a process for feeding a pet food supplement or diet for providing weight loss in a canine by providing an effective amount of L-carnitine in the diet of the animal. It is also a feature of the present invention to provide a pet food supplement or diet which increases the lean body mass of the animal. It is also a feature of the present invention to provide a pet food supplement which enhances satiety and reduces voluntary food intake in a canine. These and other features and advantages of the invention will become apparent from the following detailed description, the accompanying drawings, and the appended claims.

Reference will now be made, by way of example, to the accompanying drawings in which:

Fig. 1 is a chart illustrating comparative percent body weight change in dogs consuming an L-carnitine supplemented diet versus a non-supplemented diet;

Fig. 2 is a chart illustrating dietary intake in dogs consuming an L-carnitine supplemented diet;

Fig. 3 is a chart illustrating the body weight of dogs during *ad libitum* and restricted feeding of an L-carnitine supplemented diet;

Fig. 4 is a chart illustrating body fat in overweight dogs before and after 49 days of *ad libitum* feeding of an L-carnitine supplemented diet;

Fig. 5 is a chart illustrating the body fat of dogs during *ad libitum* and restricted feeding of an L-carnitine supplemented diet;

Fig. 6 is a chart illustrating the lean body mass of dogs during *ad libitum* and restricted feeding of an L-carnitine supplements diet; and

Fig. 7 is a chart illustrating the relationship of weight loss to food intake of dogs during *ad libitum* and restricted feeding of an L-carnitine supplemented diet.

Dietary supplementation of L-carnitine in amounts of from between about 15 to about 195 ppm, more preferably between about 20 to about 150 ppm, and most preferably about 50 to about 100 ppm, promotes weight loss in overweight canines.

-4-

Where an effective amount of L-carnitine is fed to dogs that are overweight, this resulted in a greater weight loss than animals fed a diet containing no supplemental L-carnitine. Further, the animals fed an L-carnitine-supplemented diet exhibited a greater percentage of lean body mass(LBM) than animals fed the same diet, but with
5 no L-carnitine supplementation. Also, animals fed an L-carnitine-supplemented diet voluntarily restricted their food intake.

The L-carnitine may be provided in a diet which can comprise any suitable pet food formulation which also provides adequate nutrition for the animal. For example, a typical canine diet for use in the present invention may contain about 18-40 wt%
10 crude protein, about 4-30 wt% fat, and about 2-20 wt% total dietary fiber. However, no specific percentages or ratios are required. Preferably, the animal is fed a low-fat L-carnitine-supplemented diet to promote weight loss. A typical low-fat diet may contain about 21.1 wt% protein, about 8.6 wt% fat, and about 1.7 wt% crude fiber. L-carnitine may also be supplied to the canine as a separate dietary supplement such
15 as, for example, in the form of a pill, biscuit, or treat.

In order that the invention may be more readily understood, reference is made to the following example which is intended to illustrate the invention, but not limit the scope thereof.

Example

20 Thirty adult ovariohysterectomized female beagle dogs were used to study the effects of L-carnitine supplementation on weight loss. All of the animals were current on their vaccination and parasite prevention program. The dogs were housed individually in oversize pens and identified by a unique ear tattoo. Fresh water was provided ad libitum during the entire study period. Food intake was adjusted as
25 necessary to achieve the desired weight for the study period.

Three dietary treatments were evaluated. The study consisted of three periods: weight gain, maintenance, and weight loss. During the eleven-week weight gain period, all dogs were fed a single diet Eukanuba Veterinary Diets® Nutritional Recovery Formula™ which contains 36.1 wt% protein, 26.1 wt% fat, and 2.1 wt%
30 crude fiber) ad libitum.

-5-

At the initiation of the maintenance phase of the study (baseline or day 0), the dogs were randomized based on body weight into three dietary treatment groups of ten dogs each with a three day feed transition period starting on day 0. Each treatment group was randomly assigned to one of three low-fat diets (Table 1). The only difference between diets was the addition of 0, 50, or 100 ppm supplemental L-carnitine. No differences in the initial body weight or body condition score existed between groups.

Table 1. Chemical composition of the low-fat diets

Nutrient	Amount of Supplemental Carnitine		
	0 ppm	50 ppm	100ppm
Protein, %	20.85	21.25	21.17
Ash	5.54	5.47	5.64
Fat	8.80	8.45	8.46
Crude Fiber	1.55	1.63	1.82
Calcium	0.89	0.92	0.81
Phosphorus	0.69	0.68	0.69
Gross Energy, kcal/g	4.69	4.67	4.63
Carnitine, ppm	21.48	73.12	126.10

The dogs were on 100% experimental diet on day 3 and were fed ad libitum during the seven-week maintenance phase of the study.

During the twelve-week weight loss phase of the study, the same experimental diets were offered as during the maintenance phase. However, the food intake was decreased to produce approximately 1.5 to 2.5% body weight loss per week. Exact amounts of experimental diets were fed to the dogs at approximately the same time each day, and remaining feed amounts were weighed the following day. Food intake and body weight were monitored daily and weekly, respectively. Whole body composition using the Dual Energy X-ray Absorptiometer (DEXA), and blood samples for CBC and chemistry were collected periodically during the study. *Whole Body*

Composition by Dual Energy X-ray Absorptiometry. The dogs were scanned with a Hologic QDR-2000 Plus Dual-Energy X-Ray Absorptiometry (DEXA) bone densitometer, supported with Hologic MXA software, version 8.0. All dogs were anesthetized and placed on the Dual Energy X-ray Absorptiometry (DEXA) table in dorsal recumbency, with legs stretched caudally to avoid overlap of the legs over the body. The dogs were scanned using the Enhanced Array Whole Body software. The body composition measurements recorded consisted of surface area (cm²), bone mineral content (BMC), bone mineral density (BMD), lean mass, fat content, percent fat, and estimated body weight. All measurements were reported in grams except for percent fat and area (cm²). Percent lean and percent BMC were calculated from the lean mass, BMC, and estimated body weight data from the DEXA results.

Anesthesia. The whole body composition was performed concomitantly and under anesthesia. The anesthetic regimen consisted of Atropine (0.01 mg/lb) as a pre-anesthetic, the combination Xylazine/Telazol/Torbugesic (0.8/6.7/0.13 mg/kg) as induction and Isoflurane (Aerrane, Ohmeda Pharmaceutical Products, Liberty Corner, NJ) as a maintenance agent using a nose cone.

Statistical analysis. A repeated measure classification analysis of variance was used to study "Treatment" and time dependent "Treatment x Time" effects (Gill and Hafs, *J. Animal Sci.* 33(2):331(1971)). The variables from the complete blood count, blood chemistry, body composition and body weights were studied using this analysis. All F-tests and mean separations using the Least Square Difference (LSD) used 0.05 Type 1 Error rate. One degree of freedom comparisons between experimental diets B versus C (comparison 1) and A versus B and C (comparison 2) were computed for the body composition and body weight variables. Comparisons 1 and 2 form an orthogonal set. An α of 0.05 was used to test for non-zero value of the mean of the two groups defined per contract. The "Treatment x Time" interaction was investigated by computing a test for linear, quadratic, and cubic response over time for each treatment. Then a test of parallelism, equal quadric response and equal cubic response was done to test equality of trend in response among treatments. An α of 0.05 for the F-tests was used in all cases. All computations were done using

SAS (statistical analysis system) software (1989).

Body Weights. The animals were randomized based on body weights and subjective body condition scores at the initiation of the maintenance period and the body weights were not different ($P>0.05$) between treatment groups at that time. The body weight curves remained somewhat parallel during all periods (weight gain, maintenance and weight loss) of the study (See, Fig. 3). During the maintenance and weight loss periods, all groups lost body weight linearly as days progressed. The linear decrease in body weight was greater ($P<0.05$) for diet B (50 ppm) than diet A (control). The linear decrease of diet C (100 ppm) was intermediate and not different ($P>0.05$) from either diets A or B. However, the repeated measure analysis revealed that the body weights of all treatment groups were different ($P<0.05$) at the initiation, mid-point and termination of the weight loss period with treatments A, C, and B having the highest, intermediate, and lowest average body weight, respectively, throughout the study (See, Table 2 below).

Whole Body Composition by DEXA. The only parameters altered by the test diets were the fat compartment and estimated body weight. All other parameters measured by DEXA were not affected by treatments. The repeated measure analysis revealed that the fat compartment was not different ($P>0.05$) at the initiation of the study, but all test diets resulted in a very significant ($P<0.001$) time dependant weight and fat loss as the study progressed. At the initiation and mid-point of the weight loss period, the estimated body weight and fat compartment were different ($P<0.05$) for all test diets with test diets A, C, and B having the highest, intermediate and lowest averages, respectively. The estimated body weights were also different ($P<0.05$) at the termination of the weight loss period between the three test diets with the same relationship between test diets as for the mid-point. At the termination of the weight loss period, the fat compartment was significantly larger ($P<0.05$) for test diet A than for test diets B or C, but test diet B was not different ($P>0.05$) from test diet C. Table 2 summarizes the body fat means for each time point measured.

-8-

Table 2

Influence of experimental diets on body fat and weight at baseline (initiation of maintenance period) and during the weight loss period (Means \pm STD).

5	Diet	Baseline	Initiation	Mid-Point	Termination
			Weight Loss*	Weight Loss*	Weight Loss*
	Fat (grams):				
	A	6196±1069	5595±994 ^a	5246±891 ^a	4590±989 ^a
	B	5989±1443	4871±1150 ^b	4435±932 ^b	3772±819 ^b
	C	6201±1344	5244±1244 ^c	4824±1312 ^c	4028±1445 ^b
10	Body Weight (kg):				
	A	14.9±1.8	14.5±2.0 ^a	13.9±1.7 ^a	13.0±1.6 ^a
	B	14.8±2.7	13.4±2.1 ^b	12.7±1.8 ^b	12.1±1.8 ^b
	C	15.0±1.8	14.0±1.6 ^c	13.4±1.6 ^c	12.6±1.6 ^c

* Means with different superscript within the same column are statistically

significantly different ($P < 0.05$).

The relative percent change in fat and estimated body weight from baseline revealed a significant difference ($P < 0.05$) between test diet A and test diets B and C (See, Fig. 4). However, test diets B and C were not different ($P > 0.05$) from each other. The relative percent change in BMC from baseline indicated that test diet A lost less ($P < 0.05$) bone mineral content than test diet B. No differences ($P > 0.05$) were noted between test diets A and C or test diets B and C for the relative percent change in BMC.

Hematology and Blood Chemistry. A time/treatment interaction was detected for the white blood cell (WBC) and the red blood cell (RBC) counts. The WBC tended to decrease as the study progressed for all test diets and the RBC had a more erratic behavior. Nevertheless, these two parameters remained within normal limits for the whole duration of the study. The other hematologic parameters evaluated were not significantly different ($P > 0.05$) between treatments.

A time/treatment interaction was also detected for several blood chemistry

-9-

parameters, namely glucose, cholesterol, triglycerides, phosphorous, and the enzyme LDH. All test diets resulted in a significant decrease ($P < 0.05$) in blood glucose over time. Although blood glucose levels were different between test diets at several time points, no distinct trend differentiated the effect of one test diet from the others. Test diets B and C tended to decrease the cholesterol levels during treatment but it increased again to meet initial values at the termination of the weight loss study. The cholesterol levels of test diet A was erratic. Although cholesterol levels were different between test diets at several time points, no distinct trend differentiated the effect of one test diet from the others and the cholesterol remained within normal limits during the course of the study. The triglyceride levels increased as the dogs were losing body weight. Test diet B resulted in the highest triglyceride levels ($P < 0.05$) at the end of the study followed by test diet A and then test diet C. The triglyceride levels remained within normal limits throughout the study except for test diet B which exceeded normal limits toward the end of the weight loss period. Although statistical differences were observed for LDH and phosphorous between test diets for several time points, only erratic response patterns were observed for all test diets and the LDH and phosphorous levels remained within normal limits throughout the study.

The groups of overweight dogs were fed the respective low-fat diets for seven weeks. As illustrated in Fig. 1, dogs which were fed diets containing supplemental carnitine of 50 and 100 ppm, respectively, achieved a body weight change of -6.4% and -5.7%, respectively, while the control group of dogs (no carnitine supplementation) exhibited only a -1.8% body weight change ($P < 0.05$ from control fed dogs).

This greater weight loss appeared to occur due to decreased dietary intake. That is, as illustrated in Fig. 2, during seven weeks of feeding, the control group of dogs voluntarily consumed an average of 1695 g/week of the diet, while the carnitine-supplemented groups voluntarily consumed an average weekly amount of only 1574 g/week (50 ppm carnitine) and 1567 g/week (100 ppm carnitine), respectively. Hence, carnitine supplementation promoted satiation as illustrated by the reduced diet intake.

-10-

A further benefit of the supplemental carnitine in the dogs' diets was that it promoted an improved body composition of the animals as shown in Table 3 below. As a result of the seven weeks of being fed the experimental diets, lean body mass in the animal (muscle) expressed as a percent of the total body mass was increased for
5 those dogs which were fed the carnitine supplemented diets. As a consequence, fat mass expressed as a percent of the total body mass was decreased with supplemental carnitine.

Table 3. Influence of carnitine on body composition in dogs

Supplemental Carnitine	Body Component	Week 0	Week 7
0	LBM ^a	55.7%	58.2%
50	LBM	56.0	60.5
100	LBM	55.9	59.5
0	Fat mass	42.7	40.3
50	Fat mass	42.4	37.8
100	Fat mass	42.5	38.9
0	BMC ^b	1.5	1.5
50	BMC	1.6	1.7
100	BMC	1.6	1.6

^a LBM = Lean Body Mass

^b BMC = Bone Mineral Content

The dogs gained an average of 14% body weight and had an average of 42.5% body fat at the end of the weight gain period. The animals lost an average of 15% of their body weight during the maintenance and weight loss phases of the experiment. See, Figs. 3 and 4. As shown in Fig. 4, 50 and 100 ppm supplemented L-carnitine resulted in more body fat loss ($P<0.05$) compared to 0 ppm supplementation when the difference in body fat between day 0 and day 49 was expressed as a percentage of day 0.

More fat mass was lost ($P<0.05$) with L-carnitine supplementation. As shown in Fig. 5, 50 and 100 ppm supplemented L-carnitine resulted in more body fat loss ($P<0.05$) compared to no (0 ppm) supplementation when the difference in body fat between day 0 and each subsequent time point (day 49, day 92, and day 133) was expressed as a percentage of day 0.

Lean body mass of the animals numerically increased with L-carnitine supplementation. As shown in Fig. 6, 50 and 100 ppm supplemented L-carnitine resulted in a leaner body mass for the animals than with no supplementation.

-12-

L-carnitine supplementation resulted in a greater ($P < 0.05$) body weight loss per quantity of food consumed. As shown in Fig. 7, 50 and 100 ppm supplemented L-carnitine resulted in a greater total weight loss per total food intake for the animals than with no supplementation.

- 5 While certain representative embodiments and details have been shown for purposes of illustrating the invention, it will be apparent to those skilled in the art that various changes in the methods and apparatus disclosed herein may be made without departing from the scope of the invention, which is defined in the appended claims.

-13-

CLAIMS


1. The use of L-carnitine (1) for promoting weight loss and/or for (2) for increasing the lean body mass and/or (3) enhancing the satiety and decreasing voluntary food intake in overweight dogs.
- 5 2. The use of L-carnitine as claimed in claim 1 in which said L-carnitine is administered in a diet containing supplemental L-carnitine in an amount of from about 15 to about 195 mg/kg of diet.
3. The use of L-carnitine as claimed in claim 1 in which said L-carnitine is administered in a diet containing supplemental L-carnitine in an amount of from about
10 25 to about 150 mg/kg of diet.
4. The use of L-carnitine as claimed in claim 2 in which said diet comprises from about 18 to 40 wt% crude protein, about 4 to 30 wt% fat, and about 2 to 20 wt% total dietary fiber.
5. The use of L-carnitine as claimed in claim 2 in which said L-carnitine is present
15 in said diet in a concentration of between about 15 to about 195 ppm.
6. The use of L-carnitine as claimed in claim 2 in which said L-carnitine is present in said diet in a concentration of between about 25 to about 150 ppm.
7. The use of L-carnitine as claimed in claim 2 in which said L-carnitine is present in said diet in a concentration of about 50 to about 100 ppm.
- 20 8. The use of L-carnitine as claimed in claim 2 in which said diet comprises about 21.1 wt% crude protein, about 8.6 wt% fat, and about 1.7 wt% crude fiber.

-14-

9. The use of L-carnitine as claimed in claim 1 in which said L-carnitine is administered as a supplement in an amount between about 1 to about 100 mg L-carnitine per day.
10. The use of L-carnitine as claimed in claim 1 in which said L-carnitine is
5 administered as a supplement in an amount of from between about 2.5 to about 50 mg L-carnitine per day.
11. A composition for promoting weight loss in a canine comprising a diet containing from about 18 to 40 wt% crude protein, about 4 to 30 wt% fat, and about 2 to 20 wt% total dietary fiber, said composition including from between about 15 to
10 about 195 ppm supplemental L-carnitine.
12. A composition as claimed in claim 11 including from between about 25 to about 150 ppm supplemental L-carnitine.
13. A composition as claimed in claim 11 in which said diet comprises about 21.1 wt% crude protein, about 8.6 wt% fat, and about 1.7 wt% crude fiber.
- 15 14. A food supplement for a canine, said supplement comprising between about 1 to about 100 mg L-carnitine.

1 / 7

Fig. 1



2/7

Fig. 2




Fig. 3




Fig. 4






Fig. 5




6/7

Fig. 6



7/7

Fig. 7



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/14009

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A23K1/00 A23K1/18 A23K1/16 A61K31/205

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K A23K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 626 849 A (HASTINGS ET AL.) 6 May 1997 (1997-05-06) column 3, line 40 - line 64	1, 14
A	claims 1, 13	2, 3, 5-7, 9, 10
X	--- PATENT ABSTRACTS OF JAPAN vol. 15, no. 275 (C-849) & JP 03 094655 A (OTSUKA PHARMACEUT CO LTD) abstract --- -/---	11, 12, 14



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 October 1999

Date of mailing of the international search report

29. 10. 1999

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Lepretre, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/14009

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y A	<p>US 5 540 917 A (ISLER ET AL.) 30 July 1996 (1996-07-30) column 1, line 54 - line 61</p> <p>column 1, line 62 - column 2, line 2 column 2, line 20 - line 26 column 3, line 24 - line 29 column 4, line 7 - line 14; example 1 column 5, line 46 - line 58 example 4</p>	1 4,8,11, 13
Y	<p>M.F. MCCARTY: "Promotion of Hepatic Lipid Oxidation and Glucogenesis as a Strategy for Appetite Control" MEDICAL HYPOTHESES, vol. 42, 1994, pages 215-225, XP000654151 page 217 page 219 page 221</p>	1
A	<p>FR 2 735 331 A (MANIA VENANCE) 20 December 1996 (1996-12-20) claims 2,3</p>	1-14
A	<p>WO 92 16218 A (LONZA INC.) 1 October 1992 (1992-10-01) examples; tables</p>	1-14
A	<p>US 5 030 458 A (SHUG ET AL.) 9 July 1991 (1991-07-09) column 1, line 12 - line 17 column 2, line 10 - line 17 column 4, line 66 - column 5, line 8 column 5, line 9 - line 10 table 1</p>	1-14
A	<p>WO 89 10065 A (SHUG ET AL.) 2 November 1989 (1989-11-02) claims 5-7</p>	1-14
A	<p>DE 39 04 109 A (SIGMA-TAU INDUSTRIE FARMACEUTISCHE RIUNITE S.P.A.) 24 August 1989 (1989-08-24) claims</p>	1-14

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 14009

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-10
because they relate to subject matter not required to be searched by this Authority, namely:
see further information sheet
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims 1-10

The content of claims 1-10 is directed to a therapeutical method which is not regarded as industrial applicable (see art. 17(2)(a)(i) PCT, Rule 39).

The search has although been carried out for all the claims, in case claims 1-10 would be amended in an acceptable format (i.e. second (non-) medical use claim). In respect to claims 1-10 the search is directed to the medical indication of weight loss (etc.) in overweight dogs attributed to L-carnitine.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/14009

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5626849 A	06-05-1997	NONE	
JP 03094655 A	19-04-1991	NONE	
US 5540917 A	30-07-1996	US 5447953 A AU 4139693 A CA 2098167 A EP 0575846 A JP 6062758 A NZ 247927 A ZA 9304351 A	05-09-1995 06-01-1994 25-12-1993 29-12-1993 08-03-1994 26-09-1995 27-12-1993
FR 2735331 A	20-12-1996	NONE	
WO 9216218 A	01-10-1992	AU 1888292 A CA 2106274 A,C EP 0576596 A JP 2667055 B JP 6507784 T US 5192804 A	21-10-1992 23-09-1992 05-01-1994 22-10-1997 08-09-1994 09-03-1993
US 5030458 A	09-07-1991	AT 105997 T AU 7322791 A CA 2045597 A DE 69009176 D DE 69009176 T DK 455808 T EP 0455808 A ES 2054492 T JP 4505400 T WO 9107880 A US 5186817 A	15-06-1994 26-06-1991 28-05-1991 30-06-1994 08-09-1994 20-06-1994 13-11-1991 01-08-1994 24-09-1992 13-06-1991 16-02-1993
WO 8910065 A	02-11-1989	US 4883672 A AU 640610 B AU 3571489 A CA 1336505 A DE 68922064 D DE 68922064 T EP 0365664 A JP 2926820 B JP 3500007 T	28-11-1989 02-09-1993 24-11-1989 01-08-1995 11-05-1995 03-08-1995 02-05-1990 28-07-1999 10-01-1991
DE 3904109 A	24-08-1989	IT 1219448 B BE 1002000 A CH 678481 A FR 2627063 A	18-05-1990 15-05-1990 30-09-1991 18-08-1989